voltage-gated calcium channel

Pathways Recommended:	Membrane Transporter/Ion Channel

By Targets:	Calcium Channel (20) Calmodulin (1) Potassium Channel (1) Sodium Channel (2) TRP Channel (2) Adrenergic Receptor (1) FKBP (1) Fluorescent Dye (1) Histamine Receptor (1) Monoamine Transporter (2)
By Research Areas:	Cancer (3) Endocrinology (2) Infection (1) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (19)

Targets Recommended: Calcium Channel HCN Channel CRAC Channel VDAC CaSR Calmodulin Chloride Channel TRP Channel Sodium Channel Potassium Channel Piezo Channel

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156664

Calcium Channel antagonist 3	Calcium Channel	Neurological Disease
Calcium Channel antagonist 3 (compound 397) is an inhibitor of voltage-gated calcium channels with an IC₅₀ value of 5-20μM .

HY-156669

Calcium Channel antagonist 4	Calcium Channel	Neurological Disease
Calcium Channel antagonist 4 (compound 189) is an inhibitor of voltage-gated calcium channels with an IC₅₀ value of 5-20μM .

HY-P5817

ω-Conotoxin CVIB	Sodium Channel	Neurological Disease
ω-Conotoxin CVIB is a non-selective *N- and P/Q-type voltage-gated* calcium channels (VGCCs) antagonist. ω-Conotoxin CVIB inhibits depolarization-activated whole-cell VGCC currents in dorsal root ganglion (DRG) neurons with a pIC₅₀** of 7.64 .

HY-148866

Cavα2δ1&NET-IN-3	Calcium Channel	Neurological Disease Endocrinology
Cavα2δ1&NET-IN-3 (example 216) is an inhibitor of the *subunit α2δ of voltage-gated* calcium channels (VGCC) and noradrenaline transporter (NET). Cavα2δ1&NET-IN-3 has K_i*s of 100-500 nM for human α2δ-1 subunit of Ca_v2.2 calcium* channel and NET, respectively .

HY-142240

Crisugabalin

HSK16149
Calcium Channel Neurological Disease

Crisugabalin (HSK16149) is a novel ligand of voltage-gated calcium channel (VGCC) α 2 δ subunit.

Crisugabalin HSK16149	Calcium Channel	Neurological Disease
Crisugabalin (HSK16149) is a novel ligand of voltage-gated calcium channel (VGCC) α 2 δ subunit.

HY-P5142

ω-Hexatoxin-Hv1a ω-ACTX-Hv1; ω-Atracotoxin-HV1	Calcium Channel	Neurological Disease
ω-Hexatoxin-Hv1a is a neurotoxin that can be isolated from the venom spider (Hadronyche versuta).ω-Hexatoxin-Hv1a blocks voltage-gated **calcium channels** .

HY-148862

Cavα2δ1&NET-IN-1	Calcium Channel Monoamine Transporter	Inflammation/Immunology
Cavα2δ1&NET-IN-1 (Compound 59S) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Ca_vα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-1 inhibits Ca_vα2δ-1 with a K_i of 112 nM. Cavα2δ1&NET-IN-1 inhibits NET with a K_i of 383 nM and IC₅₀ of 67 nM. Cavα2δ1&NET-IN-1 can be used for research of pain .

HY-148863

Cavα2δ1&NET-IN-2	Calcium Channel Monoamine Transporter	Inflammation/Immunology
Cavα2δ1&NET-IN-2 (Compound 45CS) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Ca_vα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-2 inhibits Ca_vα2δ-1 with a K_i of 454 nM. Cavα2δ1&NET-IN-2 inhibits NET with a K_i of 59 nM and IC₅₀ of 7 nM. Cavα2δ1&NET-IN-2 can be used for research of pain .

HY-P5179

Huwentoxin I HWTX-I	Calcium Channel Sodium Channel	Neurological Disease
Huwentoxin I (HWTX-I) is a peptide toxin that inhibits voltage-gated sodium channels and N-type **calcium channels*. Huwentoxin I inhibits sodium channels* in rat hippocampus and cockroach dorsal unpaired median (DUM) neurons with IC₅₀ values of 66.1 and 4.80 nM, respectively .

HY-D2266

FluoBar1	Fluorescent Dye	Neurological Disease
FluoBar1 is an imaging fluorescence probe modified by a barbiturate ligand with fluorescent coumarin. FluoBar1 can monitor L-type voltage-gated calcium channels (LTCC) in living cells in real time for the study of neurological diseases .

HY-P2699

ω-Grammotoxin SIA GrTx; ω-GsTx SIA	Calcium Channel	Neurological Disease
ω-Grammotoxin SIA (GrTx) is P/Q and N-type voltage-gated **Calcium channels** inhibitor. ω-Grammotoxin SIA is also a protein toxin that can be obtained from spider venom. ω-Grammotoxin SIA has the potential to study neurological diseases as well as cardiovascular diseases .

HY-132932

Cavα2δ-IN-1

Calcium Channel Others

Cavα2δ-IN-1 shows high selectivity for voltage-gated calcium channels Cavα2δ-1 (K_i 6 nM) versus Cavα2δ-2 (K_i ＞ 10000 nM).

Cavα2δ-IN-1	Calcium Channel	Others
Cavα2δ-IN-1 shows high selectivity for voltage-gated calcium channels Cavα2δ-1 (K_i 6 nM) versus Cavα2δ-2 (K_i ＞ 10000 nM).

HY-N7503

Psoralenoside	Histamine Receptor Calcium Channel Calmodulin	Infection Metabolic Disease Cancer
Psoralenoside is a benzofuran glycoside from Psoralea corylifolia . Psoralenoside exhibits high binding affinities against histaminergic H₁, calmodulin, and voltage-gated L-type **calcium channels** (E-value≥-6.5 Kcal/mol) . Psoralenoside shows estrogen-like activity, osteoblastic proliferation accelerating activity, antitumor effects and antibacterial activity .

HY-106345

ILS-920	FKBP Calcium Channel	Neurological Disease Inflammation/Immunology
ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin FKBP52 and to the β1-subunit of *L-type voltage-gated* calcium channels (VGCC). ILS-920 shows 200-fold selectivity for FKBP52** versus FKBP12 .

HY-P1427A

Guangxitoxin 1E TFA	Potassium Channel	Neurological Disease
Guangxitoxin 1E TFA is the TFA salt form of Guangxitoxin 1E (HY-P1427). Guangxitoxin 1E TFA is a peptide toxin and a selective inhibitor for voltage-gated potassium channel K_V2.1 and K_V2.2 with IC₅₀ of 1-3 nM. Guangxitoxin 1E TFA enhances glucose-stimulated intracellular calcium ion oscillations and increases insulin secretion in a glucose-dependent manner .

HY-B0768A

Lomerizine dihydrochloride

KB-2796
Calcium Channel Neurological Disease

Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.
HY-B0768

Lomerizine

KB-2796 free base
Calcium Channel Neurological Disease

Lomerizine is an antagonist of L- and T-type voltagegated calcium channels.

Lomerizine dihydrochloride KB-2796	Calcium Channel	Neurological Disease
Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.

Lomerizine KB-2796 free base	Calcium Channel	Neurological Disease
Lomerizine is an antagonist of L- and T-type voltagegated calcium channels.

HY-108006

Mirogabalin besylate 1 Publications Verification DS 5565 besylate	Calcium Channel	Neurological Disease
Mirogabalin besylate is a selective and orally available ligand for the α2δ subunit of **voltage-gated calcium channels, with K_d**s of 13.5 nM, 22.7 nM, 27 nM, and 47.6 nM for human α2δ-1, human α2δ-2, rat α2δ-1, and rat α2δ-2, respectively.

HY-P1651

SOR-C13	TRP Channel	Cancer
SOR-C13, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC₅₀ value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 has anticancer activity .

HY-P1078

Huwentoxin XVI	Calcium Channel	Neurological Disease
Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC₅₀ of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P1078A

Huwentoxin XVI TFA	Calcium Channel	Neurological Disease
Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC₅₀ of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P1651A

SOR-C13 TFA	TRP Channel	Cancer
SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC₅₀ value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity .

HY-B0768AR

Lomerizine dihydrochloride (Standard)	Calcium Channel	Neurological Disease
Lomerizine dihydrochloride (Standard) is the analytical standard of Lomerizine dihydrochloride. This product is intended for research and analytical applications. Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.

HY-111828

TTA-A2 1 Publications Verification	Calcium Channel	Neurological Disease
TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a₁G) and Cav3.2 (a₁H) channels with IC₅₀ values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy .

HY-P5820

ω-Conotoxin Bu8	Calcium Channel	Neurological Disease
ω-Conotoxin Bu8 is a ω-conotoxin, which consists of 25 amino acid residues and three disulfide bridges. ω-Conotoxin Bu8 selectively and potently inhibits depolarization-activated Ba₂₊ currents mediated by rat CaV2.2 expressed in HEK293T cells (IC₅₀= 89 nM) .

HY-132184

5,6-Epoxyeicosatrienoic acid 5,6-EET; (±)5,6-EpETrE	Adrenergic Receptor	Endocrinology
5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC₅₀=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone.

Cat. No.	Product Name

HY-L119

Potassium Channel Compound Library	219 compounds
Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. There are four major classes of K channels: voltage-gated potassium channel, calcium-activated potassium channel, inwardly rectifying potassium channel and tandem pore domain potassium channel. There is growing evidence that dysfunction in potassium channels correlates with several diseases, such as chronic hypertension, diabetes, hypercholesterolemia and atherosclerosis, etc. MCE Potassium Channel Compound Library consists of 219 potassium channel inhibitor and activators, which is a useful tool to discover drugs for cardiovascular diseases and potassium channel research.

Potassium Channel Compound Library

219 compounds

Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. There are four major classes of K channels: voltage-gated potassium channel, calcium-activated potassium channel, inwardly rectifying potassium channel and tandem pore domain potassium channel. There is growing evidence that dysfunction in potassium channels correlates with several diseases, such as chronic hypertension, diabetes, hypercholesterolemia and atherosclerosis, etc.

MCE Potassium Channel Compound Library consists of 219 potassium channel inhibitor and activators, which is a useful tool to discover drugs for cardiovascular diseases and potassium channel research.

HY-L0104V

UORSY New Generation Screening Library	1,900,000 compounds
UORSY New Generation Screening Library contains about 1,900,000 compounds. The library is a revolutionary collection of lead-like molecules with outstanding structural quality and diversity—New Generation Screening Library (NGSL). Its core is decorated with interesting building blocks, including important medicinal fragments such as peptide bonds, amino groups and hydroxyl groups. and designed for discovery of new Voltage-gated calcium channel blockers.

UORSY New Generation Screening Library

1,900,000 compounds

UORSY New Generation Screening Library contains about 1,900,000 compounds. The library is a revolutionary collection of lead-like molecules with outstanding structural quality and diversity—New Generation Screening Library (NGSL). Its core is decorated with interesting building blocks, including important medicinal fragments such as peptide bonds, amino groups and hydroxyl groups. and designed for discovery of new Voltage-gated calcium channel blockers.

Cat. No.	Product Name	Type